MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced that the company will present four posters at the American Association for Cancer Research (AACR) Annual Meeting being held this year in Chicago, Illinois from April 14-18, 2018.
Following is a list of abstracts that will be presented at the meeting.
|
Session ID / |
Title & Presenter | Day & Time | Location | |||||||||
|
PO.BSB01.01 |
Methods
of improving accuracy of neoantigen identification for therapeutic
and diagnostic use in immuno-oncology |
April 16; |
Poster |
|||||||||
|
PO.BSB01.02 |
Deconvolution
of diverse immune cell populations within tumors using ACE
Transcriptome |
April 16; |
Poster |
|||||||||
|
PO.MCB09.08 |
Supporting
neoantigen discovery and monitoring in plasma through analytical
validation of a deep Augmented Content Enhanced (ACE) exome |
April 18; |
Poster |
|||||||||
|
PO.IM02.04 |
Molecular
profiling of anti-PD-1 treated melanoma patients reveals
importance of assessing neoantigen burden and tumor escape
mechanisms for clinical treatment |
April 18; |
Poster |
|||||||||
About Personalis, Inc.
Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.
The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
